ELMO3 predicts poor outcome in T1 laryngeal cancer

Objectives Despite the excellent overall survival of 92%‐97% in early glottic cancer, recurrence rates of 13%‐20% have not improved in the last decades. The engulfment and cell motility protein 3 (ELMO3) have been described as prognostic marker in patients with lung cancer. The aim of this study was...

Full description

Saved in:
Bibliographic Details
Published in:Clinical otolaryngology 2017-12, Vol.42 (6), p.1181-1186
Main Authors: Haymerle, G., Kadletz, L., Wiebringhaus, R., Golabi, B., Mildner, M., Thurnher, D., Heiduschka, G.
Format: Article
Language:English
Subjects:
Adaptor Proteins, Signal Transducing - metabolism
Adult
Aged
Cancer
Carcinoma, Squamous Cell - metabolism
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - surgery
Cytoskeletal Proteins - metabolism
Disease-Free Survival
ELMO3
Female
Glottis
Humans
Immunohistochemistry
Laryngeal cancer
Laryngeal Neoplasms - metabolism
Laryngeal Neoplasms - mortality
Laryngeal Neoplasms - surgery
laryngeal squamous cell carcinoma
Laser Therapy
Lung cancer
Male
Microsurgery
Middle Aged
Neoplasm Staging
outcome
Patients
Predictive Value of Tests
Retrospective Studies
Survival
Survival Rate
Treatment Outcome
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives Despite the excellent overall survival of 92%‐97% in early glottic cancer, recurrence rates of 13%‐20% have not improved in the last decades. The engulfment and cell motility protein 3 (ELMO3) have been described as prognostic marker in patients with lung cancer. The aim of this study was to investigate the expression of ELMO3 in early laryngeal cancer patients treated with TLM and to evaluate its prognostic significance on clinical outcome. Design, setting and participant Forty‐eight patients with glottic carcinoma (T1N0M0) that underwent primary treatment with TLM between 1994 and 2012 were analysed. ELMO3 expression of the tumour was assessed using immunohistochemistry and correlated with clinical data. Main outcome measure Overall survival, disease‐specific survival (DSS) and disease‐free survival (DFS) rates Results Positive ELMO3 expression was found in 23% of the patients and was correlated with poor DSS and DFS (P
ISSN:1749-4478
1749-4486
DOI:10.1111/coa.12845